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Abstract
Background: Animal models of non-alcoholic steatohepatitis (NASH) are important tools in preclinical research and
drug discovery. Gubra-Amylin NASH (GAN) diet-induced obese (DIO) mice represent a model of fibrosing NASH.
The present study directly assessed the clinical translatability of the model by head-to-head comparison of liver
biopsy histological and transcriptome changes in GAN DIO-NASH mouse and human NASH patients.
Methods: C57Bl/6 J mice were fed chow or the GAN diet rich in saturated fat (40%), fructose (22%) and cholesterol
(2%) for ≥38 weeks. Metabolic parameters as well as plasma and liver biomarkers were assessed. Liver biopsy
histology and transcriptome signatures were compared to samples from human lean individuals and patients
diagnosed with NASH.
Results: Liver lesions in GAN DIO-NASH mice showed similar morphological characteristics compared to the NASH
patient validation set, including macrosteatosis, lobular inflammation, hepatocyte ballooning degeneration and
periportal/perisinusoidal fibrosis. Histomorphometric analysis indicated comparable increases in markers of hepatic
lipid accumulation, inflammation and collagen deposition in GAN DIO-NASH mice and NASH patient samples. Liver
biopsies from GAN DIO-NASH mice and NASH patients showed comparable dynamics in several gene expression
pathways involved in NASH pathogenesis. Consistent with the clinical features of NASH, GAN DIO-NASH mice
demonstrated key components of the metabolic syndrome, including obesity and impaired glucose tolerance.
Conclusions: The GAN DIO-NASH mouse model demonstrates good clinical translatability with respect to the
histopathological, transcriptional and metabolic aspects of the human disease, highlighting the suitability of the
GAN DIO-NASH mouse model for identifying therapeutic targets and characterizing novel drug therapies for NASH.
Keywords: Non-alcoholic steatohepatitis, Mouse model, Diet-induced obesity, Translatability, Histopathology,
Histomorphometry, Liver transcriptome, Glucose tolerance
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Background
Non-alcoholic fatty liver disease (NAFLD) comprises a
continuum of liver lesions ranging from simple steatosis to
non-alcoholic steatohepatitis (NASH) which, in addition to
steatosis, is characterized by lobular inflammation and
hepatocellular ballooning degeneration [1]. NASH has
emerged as a major challenge for public health because of
its increasing prevalence worldwide, difficulties in diagno-
sis, risk of severe complications and lack of effective ther-
apies. The presence of the metabolic syndrome, notably
obesity and type 2 diabetes, is the strongest predisposing
factor for development and progression of NAFLD [2].
While simple steatosis usually has a benign course, patients
with NASH and fibrosis carry an increased risk of liver-
related complications, including cirrhosis, hepatocellular
carcinoma and end-stage liver disease. As a consequence,
NASH is expected soon to become the leading indication
for liver transplantation [3].
Given the lack of effective therapies for NASH, there
is a need to establish animal models that better predict
clinical responses. The increased understanding of vari-
ous pathogenic drivers acting together (‘multiple hits’) to
trigger the onset and progression of NASH has played
an important role in the development of animal models
of NASH with reproducible and robust metabolic and
liver histopathological changes [4, 5]. Although no single
rodent model of NAFLD recapitulates the full spectrum
of the human condition, the clinical and histopatho-
logical hallmarks of NASH are largely reproducible in
diet-induced obese (DIO) mice fed ‘Western’ high-fat
diets specifically modified to enhance NASH pathology
and promote liver fibrosis [5, 6], making these models
highly relevant in preclinical drug discovery [7]. In
particular, high intake of saturated fat, trans-fats, fruc-
tose and cholesterol is associated with increased risk of
NAFLD/NASH [8–10]. A prototypic example of an experi-
mental NASH-promoting diet rich in these components is
the ALIOS (American lifestyle-induced obesity syndrome)
diet initially described by Tetri and colleagues [11]. We
have further refined and validated this diet formula, termed
the Amylin liver NASH (AMLN) diet [12], for reliably indu-
cing metabolic, biochemical and liver-biopsy confirmed
histological changes recapitulating hallmarks of NASH in
C57BL/6 J (AMLN DIO-NASH) and leptin-deficient ob/ob
(AMLN ob/ob-NASH) mice. The two AMLN models have
been increasingly used in preclinical drug development for
NASH [12–20]. However, a recent regulatory ban on trans-
fats as food additive [21] has prompted the development of
a compatible Western diet capable of promoting metabolic
and liver histopathological changes similar to the AMLN
diet. We have recently reported maintained fibrotic NASH
histopathology in C57BL/6 J (GAN DIO-NASH) and ob/ob
(GAN ob/ob) mice fed a modified, trans-fat free AMLN diet
termed the Gubra Amylin NASH (GAN) diet [22].
The present study aimed to further validate the clinical
translatability of GAN diet-induced liver lesions by com-
paring liver biopsy histopathological and transcriptome
characteristics in GAN DIO-NASH mice and human
NASH patients.
Methods
Human subjects
Healthy normal-weight individuals (n = 14, body mass
index 18.5–25 kg/m2) were recruited at Center for
Clinical Metabolic Research, Gentofte Hospital, Uni-
versity of Copenhagen (Hellerup, Denmark). Normal-
weight individuals were not suffering from or showing
symptoms of liver disease or other illnesses. NASH
patients (n = 16) were diagnosed and recruited at the
Department of Hepatology and Gastroenterology,
Aarhus University Hospital (Aarhus, Denmark) as de-
scribed in detail previously [23–25]. The HOMA-IR
(homeostasis model assessment of insulin resistance)
index was calculated as [fasting plasma insulin (mU/L)
x fasting blood glucose (mmol/L)/22.5] [26], based on
fasting blood glucose and plasma insulin concentrations
reported previously [23–25]. All included participants
underwent liver biopsy for histological evaluation. Percu-
taneous liver biopsy was performed under ultrasound guid-
ance. The liver biopsy was divided into a > 10mm sample
(> 10 portal tracks) and fixed in phosphate-buffered forma-
lin for histological evaluation. The remaining sample mater-
ial was placed in RNAlater (ThermoFisher Scientific,
Waltham, MA) or snap-frozen in liquid nitrogen and stored
at − 80°C until later processing. Diagnosis of NASH was
based on confirmation of lobular inflammation and hepato-
cyte ballooning in addition to steatosis, see below.
Animals
The Danish Animal Experiments Inspectorate approved all
experiments which were conducted using internationally
accepted principles for the use of laboratory animals
(license #2013-15-2934-00784). C57BL/6 J mice (5 weeks
old) were from Janvier Labs (Le Genest Saint Isle, France)
and housed in a controlled environment (12 h light/dark
cycle, lights on at 3 AM, 21 ± 2 °C, humidity 50 ± 10%).
Each animal was identified by an implantable subcutaneous
microchip (PetID Microchip, E-vet, Haderslev, Denmark).
Mice had ad libitum access to tap water and chow (3.22
kcal/g, Altromin 1324, Brogaarden, Hoersholm, Denmark)
or Gubra Amylin NASH diet [GAN diet, 4.49 kcal/g, 40
kcal-% fat (of these 46% saturated fatty acids by weight),
22% fructose, 10% sucrose, 2% cholesterol; D09100310,
Research Diets]. Mice were fed chow or GAN diet for 38–
44 weeks. Animals were terminated by cardiac puncture
under isoflurane anesthesia.
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Histopathology scoring
Semiquantitative histopathological scoring was performed
on HE- and PSR-stained human (healthy normal-weight
individuals, n = 14; NASH patients, n = 16) and mouse
(chow-fed mice, n = 10; GAN DIO-NASH mice, n = 25)
liver samples in a blinded manner by experienced hepato-
histopathologists using the NAFLD Activity Score (NAS)
and fibrosis staging system according to the Brunt criteria,
modified by Kleiner et al. [27]. The NAS score was defined
as the unweighted sum of the scores for steatosis (0–3),
lobular inflammation (0–3), and ballooning (0–2), thus
ranging from 0 to 8. Liver fibrosis was scored based on a
five-point scale, i.e. absence of fibrosis (stage 0), perisinu-
soidal or portal fibrosis (stage 1), perisinusoidal and por-
tal/periportal fibrosis (stage 2), septal or bridging fibrosis
(stage 3), cirrhosis (and stage 4).
Liver histomorphometry
Human liver biopsies (healthy normal-weight individuals,
n = 14; NASH patients, n = 11) and mouse lobular samples
(chow-fed mice, n = 10; GAN DIO-NASH mice, n = 25)
were fixed overnight in 4% paraformaldehyde, paraffin-
embedded and sectioned (3 μm thickness). Sections were
stained with hematoxylin-eosin (HE), anti-galectin-3 (cat.
125,402, Biolegend, San Diego, CA) or picro-Sirius Red
(PSR, Sigma-Aldrich, Broendby, Denmark) using standard
procedures [28, 29]. The fractional (%) area of liver lipid
(HE-staining), inflammation (galectin-3) and fibrosis
(PSR) was expressed relative to total sectional area.
Liver RNA sequencing analysis
Liver transcriptome analysis was performed by RNA
sequencing on RNA extracts from human liver biopsies
(healthy normal-weight individuals, n = 14; NASH pa-
tients, n = 16) and mouse lobular liver samples (chow-fed
mice, n = 10; GAN DIO-NASH mice, n = 25), as described
in detail elsewhere [25, 28]. The RNA quantity was mea-
sured using Qubit® (Thermo Scientific, Eugene, OR). The
RNA quality was determined using a bioanalyzer with
RNA 6000 Nano kit (Agilent, Waldbronn, Germany). All
samples were confirmed to have high-quality RNA (RNA
integrity number ≥ 7.5). RNA sequence libraries were
prepared with NeoPrep (Illumina, San Diego, CA) using
the Illumina TruSeq stranded mRNA Library kit and
sequenced on the NextSeq 500 System (Illumina, San
Diego, CA) with NSQ 500 hi-Output KT v2 (75 CYS,
Illumina, San Diego, CA). Reads were aligned to the
GRCh38.p10 Ensembl human genome or GRCm38 v84
Ensembl Mus musculus genome using STAR v.2.5.2a with
default parameters. For both human and mouse samples,
a lower detection limit for gene expression was defined
based on raw mapped read counts (RPKM= 0.1). The R
package DESeq2 v.1.18.1 [30] was used for differential
expression analysis. P-values were adjusted using the
Benjamini-Hochberg method, and a cut-off of 0.05 (5%
False Discovery Rate, FDR) was applied. Candidate
NAFLD- and fibrosis-associated pathways were used to
annotate genes involved in disease progression (Table
S1). A gene set analysis was conducted with the R pack-
age PIANO version 1.18.1 using the Stouffer method,
and p-values were corrected for multiple testing using the
Benjamini-Hochberg method (FDR < 0.05). The Reactome
pathway database was retrieved and used as gene annota-
tion for global transcriptional changes (p < 0.05).
Glucose tolerance test
An intraperitoneal glucose tolerance test (ipGTT) was per-
formed in chow-fed mice (n = 10) and GAN DIO-NASH
mice (n = 15) one week prior to termination. Animals were
fasted for 4 h whereupon an intraperitoneal glucose bolus
(2 g glucose/kg, 10mL/kg; Fresenius Kabi, Uppsala,
Sweden) was administrated at t = 0. A baseline blood sam-
ple (− 60min) and successive blood samples during the
ipGTT (0–180min) were collected from the tail vein (20 μl
per sample) for measuring blood glucose. Glucose area
under the curve (AUC, 0–180min) was determined.
Plasma and liver biochemistry
Terminal 4 h fasting whole blood was sampled from chow-
fed mice and GAN DIO-NASH mice, kept on ice and cen-
trifuged (5min, 4 °C, 6000 x g) to generate EDTA-stabilized
plasma assayed for insulin, leptin, free fatty acids, triglycer-
ides (TG), total cholesterol (TC), alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) as described
previously [14, 28]. HOMA-IR index was calculated using
similar procedure as for clinical samples (see above). Plasma
markers for fibrosis were determined utilizing recom-
mended sample dilutions and standard curve concentrations
for total cytokeratin 18 (CK-18, #CSB-E17158m, Cusabio,
Houston, TX), matrix metalloproteinase-9 (MMP-9,
#AL519C, PerkinElmer, Waltham, MA) and tissue inhibitor
of metalloproteinase-1 (TIMP-1, #MTM100, R&D Systems,
Minneapolis, MN). Liver lobular samples from chow-fed
mice and GAN DIO-NASH mice were analyzed for TG, TC
and hydroxyprolin (HP) as reported previously [14, 28]. A
multiplex assay was applied for cytokine analysis (TNF-α,
interferon-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, KC/GRO
(CXCL1), IL12p70) in mouse plasma samples and liver
lobular homogenates according to the manufacturer’s proto-
col (#K15048G, Meso Scale Diagnostics, Rockville, MD). A
separate kit was used for analysis of plasma and liver
concentrations of mouse MCP-1 (CCL-2, #K152NND,
Meso Scale Diagnostics, Rockville, MD).
Statistical analysis
All results are shown as mean ± standard error of mean
(S.E.M.). Except from RNA sequencing, an unpaired t-
test (quantitative histology, plasma/liver biochemistry
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and plasma cytokine data) or a two-way ANOVA with
Dunnett’s multiple comparison test (ipGTT data) was
applied. A p-value < 0.05 was considered statistically
significant.
Results
Comparable liver histopathological hallmarks GAN DIO-
NASH mice and NASH patients
In order to assess the translational relevance of the mouse
model, liver histopathological changes in GAN DIO-
NASH mice were compared to liver biopsy samples from
human NASH patients. GAN DIO-NASH mice showed
similar morphological appearance of steatosis, inflamma-
tory foci and hepatocyte ballooning as compared to hu-
man NASH, see representative histological stainings in
Fig. 1. Hepatocyte lipid accumulation was distributed
throughout the liver lobule in GAN DIO-NASH mice,
appearing mainly as macrovesicular steatosis (single large
intracytoplasmic fat droplet or smaller well-defined drop-
lets), displacing the nucleus to the cell periphery. Lobular
inflammation in GAN DIO-NASH mice was characterized
by small foci of inflammatory cells showing mainly macro-
phage and lymphocyte morphology. In both GAN DIO-
NASH mice and NASH patients, hepatocyte ballooning
degeneration was observed in the centrilobular zone 3
appearing as swollen hepatocytes with pale and rarefied
cytoplasm. Perisinusoidal collagen fiber distribution in
GAN DIO-NASH mice was similar to that observed in
liver biopsy samples from NASH patients. Mild fibrosis
(stage F1) presented as periportal or perisinusoidal fibrosis
Fig. 1 Similar liver histopathological hallmarks in human NASH patients and GAN DIO-NASH mice. Upper panels: Representative
photomicrographs of liver sections from human healthy normal-weight individual (a), NASH patient (b-e), chow-fed mouse (f) and GAN DIO-
NASH mouse (g-j) stained with hematoxylin-eosin (HE, for evaluation of steatosis, inflammation and hepatocyte ballooning; a-d, f-i) or picro-Sirius
Red (PSR, for evaluation of fibrosis; e, j). Arrows indicate inflammatory foci and ballooning hepatocytes, respectively. Lower panels:
Histomorphometric quantitative assessment of liver lipid accumulation (HE staining), inflammation (galectin-3 immunostaining) and fibrosis (PSR
staining) in human and mouse liver biopsy sections. *p < 0.05, **p < 0.01, ***p < 0.001 vs. corresponding control group, unpaired t-test
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in GAN DIO-NASH mice while perisinusoidal fibrosis
was more prevalent in the NASH patient sample set.
Moderate-stage fibrosis (stage F2) with portal and central
zonation was similar in GAN DIO-NASH mice and
NASH patients.
Individual histopathological scores in mouse and human
liver biopsies are indicated in Table 1. Healthy normal-
weight human individuals had normal-range liver hist-
ology. NASH patients showed moderate-severe steatosis
(grade 2–3), mild lobular inflammation (grade 1) and mild
to prominent hepatocyte ballooning (grade 1–2). 13 out of
16 NASH patients were diagnosed with fibrosis ranging
from mild to moderate stage (F1-F2). In comparison to
normal liver histology in chow-fed control mice, all GAN
DIO-NASH mice showed severe steatosis (grade 3) with
varying severity of lobular inflammation. When present,
hepatocyte ballooning degeneration was mild (grade 1). 22
out of 25 GAN DIO-NASH mice developed liver fibrosis,
nearly all presenting mild to moderate stage fibrosis (F1-
F2). The relatively similar disease severity in NASH
patients and GAN DIO-NASH mice was reflected by com-
parable NAFLD Activity Scores (NASH patients, NAS 5–6;
GAN DIO-NASH mice, NAS 4–7), see Table 2. HOMA-
IR was significantly increased in NASH patients (7.6 ± 1.0,
p < 0.0001, n = 16) compared to healthy normal-weight in-
dividuals (1.3 ± 0.2, n = 14).
Comparable quantitative liver histopathological changes
in GAN DIO-NASH mice and NASH patients
Quantitative levels of liver fat (HE staining), inflamma-
tory cell infiltration (galectin-3 IHC) and collagen depos-
ition (PSR staining) were compared in human and
mouse liver biopsies (Fig. 1). NASH patients (n = 11)
demonstrated significant increases in the fractional (%)
area of liver fat (8-fold increase; 24.2 ± 2.6 vs. 2.9 ± 0.4%,
p < 0.0001), galectin-3 (16-fold increase; 1.6 ± 0.4 vs
0.1 ± 0.02, p = 0.0016) and PSR (2-fold increase; 3.2 ± 0.6
vs. 1.7 ± 0.2, p < 0.0122) as compared to normal-weight
healthy individuals (n = 12–14). Correspondingly, GAN
DIO-NASH mice (n = 25) showed significant increases
in % area of liver fat (25-fold increase; 29.8 ± 1.3 vs.
1.2 ± 0.2%, p < 0.0001), galectin-3 (6-fold increase; 5.0 ±
0.3 vs 0.9 ± 0.1%, p < 0.0001) and PSR (5-fold increase;
1.1 ± 0.2 vs. 0.2 ± 0.02%, p = 0.0064) as compared to
chow-fed lean mice (n = 10).
Overlapping hepatic transcriptome profiles in GAN DIO-
NASH mice and NASH patients
To compare global gene expression profiles in mouse
and human liver biopsy samples, a principal component
analysis (PCA) was performed (Fig. 2a). The primary
PCA, accounting for the major variability in the data set,
indicated that liver transcriptome profiles in healthy
normal-weight human controls were clearly separated
from the transcriptome profiles in NASH patient sam-
ples. This also applied to chow-fed controls vs. GAN
DIO-NASH mice. GAN DIO-NASH mice demonstrated
relatively homogenous gene expression changes as indi-
cated by close clustering of individual transcriptome sig-
natures. An extensive number of differentially expressed
genes (DEGs) were determined in liver biopsies from
GAN DIO-NASH mice (n = 9495) and NASH patients
(n = 6226) with a significant overlap in DEGs (n = 4418),
see Fig. 4b. A gene set enrichment analysis revealed sig-
nificant perturbations in Reactome top level signaling
pathways in GAN DIO-NASH mouse and NASH patient
samples. To a large extent, similar directional shifts in
top canonical NASH-associated pathways were detected
in GAN DIO-NASH mice and NASH patients. Reflect-
ing key metabolic and histopathological features of
NASH, most consistent pathway perturbations in GAN
DIO-NASH mice and NASH patients were associated
with nutrient metabolism, immune function and extra-
cellular matrix (ECM) organization (Fig. 2c). To obtain
further resolution of hepatic transcriptome regulations
in GAN DIO-NASH mice and NASH patients, RNA
sequencing data were probed for candidate genes linked
to NASH pathology and fibrosis (Fig. 3, Table S1). Com-
pared to NASH patients, GAN DIO-NASH mice showed
more widespread regulations within the seven defined
gene categories. Changes in gene transcriptional pro-
grams pointed to deficient glucose metabolism, impaired
lipid and bile acid handling, immunomodulation, endo-
plasmic reticulum (ER) stress, hepatocellular injury and
enhanced ECM remodeling activity (Fig. 3a). A subset of
candidate genes encode protein targets exploited for the
Table 1 Comparison of liver biopsy histopathology scores in human NASH patients and GAN DIO-NASH mice
Group n Steatosis score Inflammation score Ballooning score Fibrosis stage
0 1 2 3 0 1 2 3 0 1 2 0 1 2 3 4
Human subjects Healthy normal-weight 14 13 1 – – 14 – – 14 – – 14 – – – –
NASH 16 – – 2 14 – 16 – – 10 6 3 12 1 – –
C57BL/6 J mice Chow-fed lean mice 10 10 – – – 10 – – 10 – – 10 – – – –
GAN DIO-NASH mice 25 – – – 25 – 6 13 6 18 7 – 3 10 11 1 –
Histopathology scores in liver biopsy samples from normal controls, human NASH patients and GAN DIO-NASH mice. Histopathology was scored according to the
criteria outlined by the NASH-Clinical Research Network [27].
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treatment of NASH [7, 31, 32]. These 28 genes were
grouped into three major categories according to major
function, i.e. Lipid & Glucose metabolism, Inflammation
and ECM organization (Fig. 3b). GAN DIO-NASH mice
and NASH patients demonstrated significantly regulated
genes within each category. Twenty-five out of twenty-
eight drug target-associated genes were significantly regu-
lated in GAN DIO-NASH mice, including downregulation
of ACACA/ACC1, ACACB/ACC2, DGAT1, HMGCR,
KHK, MAP 3 K5/ASK1, MTOR, NR1H3/LXR-α, NR1H4/
FXR, THRB and upregulation of CCR2, CCR5, CYSLTR1,
FGF21, LGALS3/MAC-2, LOXL2, PPARG, SLC10A2/
Table 2 Comparison of composite NAFLD Activity Score (NAS) in human NASH patients and GAN DIO-NASH mice
NAS
Group n 0 1 2 3 4 5 6 7 8
Human subjects Healthy normal-weight 14 13 1 – – – – – – –
NASH 16 – – – – – 12 4 – –
C57BL/6 J mice Chow-fed lean mice 10 10 – – – – – – – –
GAN DIO-NASH mice 25 – – – – 6 7 11 1 –
Composite NAFLD Activity Score (NAS) in liver biopsy samples from normal controls, human NASH patients and GAN DIO-NASH mice. Histopathology was scored
according to the criteria outlined by the NASH-Clinical Research Network [27]
Fig. 2 Liver transcriptome changes in human NASH patients and GAN DIO-NASH mice. a Principal component analysis (PCA) of samples based
on top 500 most variable gene expression levels. b Venn diagram depicting shared and separate differentially expressed genes (DEGs; false
discovery rate < 0.05) in NASH patients and GAN DIO-NASH mice. c Comparison of significantly regulated disease-associated Reactome signalling
pathways in NASH patients (n = 16) and GAN-DIO NASH mice (n = 25). Reactome signalling pathways are grouped according to biological
pathway. Color gradients indicate significantly upregulated (red color) and downregulated (blue color) pathways compared to corresponding
control group (chow-fed mice, n = 10; healthy normal-weight human individuals, n = 14)
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IBAT, SERPINH1/HSP47, TLR4, TNF/TNF-α. In NASH
patient liver biopsies, similar gene expression signatures
were observed for ACACB/ACC2, DGAT1, THRB (down-
regulated) and CCR5, FGF21, LGALS3/MAC-2, SER-
PINH1/HSP47 (upregulated). In addition, NASH patients
showed downregulation of PPARA, AOC3/VAP-1,
CYSLTR1, GPBAR1/TGR5, TLR4 and upregulation of
SCD. mRNA expression of FGF15/19 and GLP1R was not
detected in mouse and human liver samples, being in
agreement with previous reports [33–35]. AOC3/VAP-1
and GPBAR1/TGR5 expression were below detection
limit in liver samples from chow-fed and GAN DIO-
NASH mice which is likely ascribed to selective ex-
pression in non-parenchymal liver cell populations
[36, 37]. In line with previous reports [38, 39],
SLC10A2/IBAT was detected in mouse, but not hu-
man, liver samples.
GAN DIO-NASH mice demonstrate impaired glucose tolerance
Compared to chow-fed controls, GAN DIO-NASH mice
showed significantly increased body weight, increased
whole-body fat mass (adiposity) and hepatomegaly at
termination (Fig. 4A-4D). An ipGTT was performed in
chow-fed and GAN DIO-NASH mice one week before
termination. While baseline and peak glucose levels were
similar in chow-fed and GAN DIO-NASH mice, glucose
excursions (t = 60–120min, p = 0.0029–0.0002) and
glucose-AUC levels (p = 0.0062) were significantly elevated
in GAN-DIO NASH mice, signifying impaired glucose
tolerance in GAN DIO-NASH mice (Fig. 4e). GAN DIO-
NASH mice demonstrated hyperinsulinemia and corres-
pondingly significantly increased HOMA-IR index com-
pared to chow-fed mice (Fig. 4f, g). GAN-DIO NASH mice
also exhibited hyperleptinemia and hypercholesterolemia
(Fig. 4h, i). While plasma free fatty acid levels tended to be
Fig. 3 Regulation of disease-associated candidate genes in NASH patients and GAN DIO-NASH mice. a Disease-associated hepatic
candidate genes, b Selected hepatic genes representing various drug targets for NASH. Color gradients indicate significantly upregulated
(red color) and downregulated (blue color) gene expression in NASH patients (n = 16) and GAN DIO-NASH mice (n = 25) compared to
corresponding control group (healthy normal-weight human individuals, n = 14; chow-fed mice, n = 10). Candidate genes are listed
in Table S1
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elevated (p = 0.05), plasma TG concentrations were un-
altered (p = 0.75) in GAN DIO-NASH mice (Fig. 4j, k).
Plasma and liver biochemical changes in GAN DIO-NASH mice
Other plasma and liver biochemical parameters analyzed
are indicated in Table 3. GAN DIO-NASH mice showed
significantly elevated levels of plasma markers of liver in-
jury (ALT, AST; both p < 0.001) and fibrosis (total CK18,
MMP-9, TIMP-1; all p < 0.0001). Compared to chow-fed
mice, GAN DIO-NASH showed significantly increased
concentrations of liver TG, TC and HP (all p < 0.0001).
Elevated liver MMP-9 levels in GAN DIO-NASH mice
did not attain statistical significance (p = 0.09).
Elevated levels of circulating and hepatic cytokines/
chemokines in GAN DIO-NASH mice
Plasma and liver cytokine/chemokine levels are shown
in Table 4. Both plasma and liver concentrations of
TNF-α (plasma, p < 0.0001; liver, p = 0.0006), KC/GRO
(CXCL1; plasma, p < 0.0001; liver, p = 0.0098) and MCP-
Fig. 4 GAN DIO-NASH mice develop characteristics of the metabolic syndrome. Terminal body weight (a), whole-body fat mass (b), whole-body
lean mass (c), liver weight (d). **p < 0.01, ***p < 0.01 (unpaired t-test; chow-fed mice, n = 6–10; GAN DIO-NASH mice, n = 14–16). An
intraperitoneal glucose tolerance test (ipGTT) was performed one week before termination. (e) Glucose excursion curves (− 60 to 180min). ***p <
0.001 (repeated-measure two-way ANOVA; chow-fed mice, n = 10; GAN DIO-NASH mice, n = 15). Insert, AUC-glucose levels (0–180min). **p < 0.01
(unpaired t-test). Terminal plasma insulin (f) and HOMA-IR (g). ***p < 0.01 (unpaired t-test; chow-fed mice, n = 10; GAN DIO-NASH mice, n = 15).
Terminal plasma leptin (h), total cholesterol (i), triglycerides (j) and free fatty acids (k). **p < 0.01, ***p < 0.01 (unpaired t-test; chow-fed mice, n =
5–10; GAN DIO-NASH mice, n = 8–15)
Hansen et al. BMC Gastroenterology          (2020) 20:210 Page 8 of 12
1 (CCL2; plasma, p = 0.0014; liver, p < 0.0001) were
significantly elevated in GAN DIO-NASH mice com-
pared to chow-fed controls. In GAN DIO-NASH mice,
most pronounced regulations were observed for hepatic
MCP-1 expression. Also, GAN DIO-NASH mice dis-
played significantly elevated plasma IL-6 (p = 0.024) and
IL-10 (p = 0.018) as well as liver IL-1β (p = 0.019) and
IL-5 (p = 0.012) concentrations.
Discussion
Given the lack of evidence-based effective therapies for
NASH, there is a marked need for animal models that bet-
ter recapitulate cardinal features of the disease. The present
study therefore assessed the clinical translatability of the
GAN DIO-NASH mouse model by performing a head-to-
head comparison of histological and transcriptome changes
in liver biopsies from GAN DIO-NASH mice and human
NASH patients. The main findings were significant clinical
translatability of the GAN DIO-NASH mouse model with
respect to the histopathological, transcriptional and meta-
bolic aspects of human NASH. This highlights the suitabil-
ity of the GAN DIO-NASH mouse model for identifying
therapeutic targets and characterizing novel drug therapies
for NASH.
Because liver diagnostic biopsy remains the definite cri-
terion for confirming and grading of NASH, we compared
liver biopsy histology in GAN DIO-NASH mice and
NASH patients using the NAFLD activity scoring (NAS)
and fibrosis staging system which is the most prevalent
tool for defining NASH and assess histological activity
[27]. GAN DIO-NASH mice showed similar pattern of
liver lesions compared to the human validation set. As
also seen in the clinic, GAN DIO-NASH mice displayed
variation in disease severity which underscores the rele-
vance of implementing liver biopsy-confirmed histopath-
ology to control for within-subject disease progression
and drug treatment efficacy in preclinical NASH models
[7]. Histopathological scoring in GAN DIO-NASH mice
recapitulated clinical criteria for diagnosing NASH. Pan-
lobular hepatocyte lipid accumulation appeared mainly as
macrovesicular steatosis in both GAN DIO-NASH mice
and NASH patients. Lobular inflammation, ranging from
mild to severe, in GAN DIO-NASH mice was character-
ized by foci consisting mainly of immune cell aggregates
with macrophage and lymphocyte morphology which
resembled human histopathology. Hepatocellular injury in
GAN DIO-NASH mouse fulfilled criteria for mild hepato-
cyte ballooning degeneration [27], as indicated by the
presence of few enlarged hepatocytes with vacuolated, rar-
ified, pale cytoplasm. The rate and severity of ballooning
injury in GAN DIO-NASH mice is similar to other high-
fat diet-induced mouse models of NASH [7, 28, 40]. GAN
DIO-NASH mice demonstrated liver fibrosis zonation
patterns comparable to NASH patients. The majority of
Table 3 Elevated plasma and liver biochemical markers in GAN DIO-NASH mice
Chow-fed C57BL/6 J mice GAN DIO-NASH mice
Plasma ALT (U/L) 29.5 ± 1.9 166 ± 16***
Plasma AST (U/L) 65.4 ± 3.8 196 ± 16.8***
Plasma total CK-18 (ng/ml) 0.11 ± 0.02 0.83 ± 0.12***
Plasma MMP-9 (pg/ml) 15,409 ± 554 21,445 ± 990***
Plasma TIMP-1 (pg/ml) 1151 ± 56 4099 ± 453***
Liver TG (mg/g tissue) 7.4 ± 0.7 94.0 ± 5.4***
Liver TC (mg/g tissue) 2.0 ± 0.1 14.1 ± 0.6***
Liver HP (μg/mg tissue) 0.03 ± 0.01 0.08 ± 0.01***
Liver MMP-9 (pg/g tissue) 183,196 ± 7725 328,529 ± 80,679
Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase, CK-18 cytokeratin-18, FFA free fatty acids, HP hydroxyproline, MMP-9 matrix
metalloproteinase-9, TC total cholesterol, TG triglycerides; TIMP-1 tissue inhibitor of metalloproteinase-1.
***p < 0.001, unpaired t-test (chow-fed mice, n = 10; GAN DIO-NASH mice, n = 15)
Table 4 Elevated plasma and liver cytokine levels in GAN DIO-
NASH mice
Cytokine/
chemokine
Chow-fed C57BL/6 J mice GAN DIO-NASH mice
Plasma
(pg/ml)
Liver
(pg/g tissue)
Plasma
(pg/ml)
Liver
(pg/g tissue)
TNF-α 7.4 ± 0.4 33 ± 2.8 15 ± 1.1*** 78 ± 9.7***
IL-1β n.d. 349 ± 46 n.d. 591 ± 79*
IL-2 n.d. n.d. n.d. n.d.
IL-4 n.d. n.d. n.d. n.d.
IL-5 1.9 ± 0.3 9.5 ± 0.7 2.0 ± 0.3 12.4 ± 0.7*
IL-6 8.2 ± 1.0 507 ± 19.7 53.7 ± 18.0* 478 ± 30
IL-10 14 ± 0.5 91 ± 7.2 18 ± 1.6* 97 ± 7.1
IL12p70 n.d. 530 ± 79 n.d. 658 ± 44
INF-γ n.d. 9.9 ± 1.1 n.d. 9.0 ± 1.9
KC/GRO 58 ± 7.4 352 ± 32 138 ± 9.8*** 640 ± 91**
MCP-1 11 ± 0.8 171 ± 9.3 30 ± 4.7** 1759 ± 304***
Plasma and liver cytokine levels in GAN DIO-NASH mice. n.d., not detected
(below lower level of quantification; IL-1β, 0.42 pg/ml; IL-2, 0.66 pg/ml; IL-4,
0.42 pg/ml; IL12p70, 7.69 pg/ml; INF-γ, 0.23 pg/ml). *p < 0.05, **p < 0.01, ***p <
0.001, unpaired t-test (chow-fed mice, n = 8; GAN DIO-NASH mice, n = 8)
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GAN DIO-NASH mice demonstrated mild or moderate
fibrotic lesions. In addition to histological confirmation of
disease hallmarks, GAN DIO-NASH mice reproducibly
showed increased levels of plasma biomarkers known to
be relevant to NAFLD/NASH diagnosis and assessment of
fibrosis risk [41–43], including markers of hepatocellular
injury (transaminases, CK-18) and ECM remodeling
(MMP-9, TIMP-1). Enhanced ECM remodeling was also
supported by liver biochemistry (HP, MMP-9).
As NAS and fibrosis scores are semiquantitative and
provide a limited range of response data, imaging-based
histomorphometry was applied for unbiased quantitative
assessment of histological changes. The quantitative
histological analysis confirmed marked lipid accumula-
tion, increased immune cell infiltration and significant
collagen deposition in GAN DIO-NASH mice and
NASH patients. Consistent with the generally higher
histopathological scores in the GAN DIO-NASH cohort
compared to the NASH patients, GAN DIO-NASH mice
showed relatively greater quantitative changes in histo-
pathological hallmarks of NASH.
Hepatic transcriptome signatures in NASH patients
and GAN DIO-NASH mice were compared and re-
vealed similar dynamics in key gene expression path-
ways involved in NASH pathogenesis. As for
histological changes, more profound changes in
disease-relevant gene expression patterns were de-
tected in GAN-DIO NASH mice. Commonalities in
pathway perturbations suggested impaired carbohy-
drate and lipid metabolism. Consistent with the role
of bile acids in NAFLD/NASH [44], NASH patients
and GAN DIO-NASH mice showed gene expression
signatures pointing to modulation of bile acid signal-
ing. Chronic hepatic inflammation represents a major
driver for development of NASH and is considered
one of the strongest independent predictors for pro-
gression into fibrosis [45]. In agreement with aberrant
innate and adaptive immune responses in NASH
pathology [46, 47], GAN DIO-NASH mice showed
gene regulations within both immune systems. Gene
markers for monocyte recruitment, migration and ac-
tivation were most consistently upregulated in GAN
DIO-NASH mice, suggesting that increased abun-
dance of pro-inflammatory macrophages play an im-
portant role in this model. In addition to activation
of genes linked to programmed cell death, NASH pa-
tients and GAN DIO-NASH mice also demonstrated
upregulated signaling pathways involved in cell cycle
control which could suggest recruitment of signaling
mechanisms related to cell division/carcinogenesis.
Notably, the gene enrichment analysis also identified
comprehensive changes in several ECM genes regulat-
ing hepatic collagen formation and turnover, support-
ing biochemical and histological evidence of extensive
ECM remodeling activity in GAN DIO NASH mice
and NASH patients. To obtain further resolution of
hepatic transcriptome regulations in GAN DIO-NASH
mice and NASH patients, RNA sequencing data were
probed for genes encoding various protein targets
exploited for the treatment of NASH, including regulators
of hepatic lipid handling, adipogenesis, peripheral insulin
sensitivity, immune cell function and ECM formation [7,
31, 32]. Compared to NASH patients, GAN DIO-NASH
mice showed more widespread regulations within the de-
fined gene set. Similar directional gene regulations in
NASH patients and GAN DIO-NASH mice were associ-
ated with fatty acid and triglyceride synthesis (ACC,
DGAT1), thyroid hormone receptor function (THRB), im-
mune cell activation (CCR5, LGALS3) and collagen matur-
ation (SERPINH1).
Corresponding to the clinical features of NASH [48],
GAN DIO-NASH mice develop characteristics of the
metabolic syndrome indicated by obesity, hypercholes-
terolemia and hyperinsulinemia with impaired glucose
tolerance, the latter being a central feature of insulin
resistance [49]. Similar to NASH patients, impaired insu-
lin sensitivity in GAN DIO-NASH mice was supported
by increased HOMA-IR, a widely used index for the esti-
mation of insulin resistance [26]. By augmenting delivery
of free fatty acids to the liver and increasing hepatic
lipogenesis, insulin resistance is recognized as an im-
portant contributing mechanism for intrahepatic lipid
accumulation and resulting lipotoxicity in NAFLD/
NASH [50, 51]. As GAN DIO-NASH mice demon-
strated profound hyperinsulinemia with normal baseline
glucose levels this points to sustained pancreatic β cell
compensation in this model. A similar insulin-resistant
phenotype has also been reported in leptin-deficient ob/
ob mice fed the GAN diet (GAN ob/ob-NASH mice)
[22], an obesity-prone accelerated model of NASH,
which lends further support to the translatability of
GAN diet-based mouse models. While the GAN and
AMLN diets induce a similar overall dysmetabolic
phenotype in C57BL/6 J and ob/ob mice, AMLN diet
feeding does not lead to manifest glucose intolerance
[12–14, 22, 28]. This phenotypic difference has been as-
cribed to the more adipogenic properties of the GAN
diet [22]. Similar to other high-fat/cholesterol diet-
induced NAFLD/NASH models in C57BL/6 mice [5],
GAN diet feeding did not promote hypertriglyceridemia.
This is likely attributed to deficient hepatic triglyceride
secretion as high-cholesterol diet feeding regimens have
been reported to downregulate endogenous cholesterol
ester and lipoprotein synthesis [52, 53]. In support of
this, GAN DIO-NASH mice showed marked liver triglycer-
ide and cholesterol accumulation together with reduced ex-
pression of several hepatic genes involved in cholesterol
synthesis and transport. Collectively, development of severe
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steatosis in GAN DIO-NASH mice is likely a combined re-
sult of high-caloric diet intake, impaired liver lipid catabol-
ism and reduced lipid clearance.
Conclusions
In conclusion, the GAN DIO-NASH mouse demonstrates
good clinical translatability with respect to the physio-
logical, metabolic and histopathological aspects of fibros-
ing NASH along with a strong concordance with the liver
transcriptome signature of the human disease. Hence, the
clear metabolic and histopathological hallmarks of NASH
highlight the suitability of the GAN DIO-NASH mouse
model for identifying therapeutic targets and characteriz-
ing novel drug therapies for NASH.
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